MX2018005259A - Inhibidores de gelatinasa y uso de los mismos. - Google Patents
Inhibidores de gelatinasa y uso de los mismos.Info
- Publication number
- MX2018005259A MX2018005259A MX2018005259A MX2018005259A MX2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- asthma
- cancer
- gelatinase
- neuropathic pain
- Prior art date
Links
- 239000002406 gelatinase inhibitor Substances 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 206010013663 drug dependence Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000036626 Mental retardation Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010051739 Pulmonary sepsis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 210000001766 X chromosome Anatomy 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000013223 septicemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Nuevos inhibidores de gelatinasa, procedimientos para su preparación, composiciones farmacéuticas que los comprenden, y su uso en la terapia y/o profilaxis de afecciones en las que la inhibición de ñas gelatinasas es útil tal como epilepsia, esquizofrenia, enfermedad de Alzheimer, autismo (en particular, asociado al síndrome del cromosoma X frágil), retraso mental, trastornos del estado de ánimo tales como trastornos bipolares, depresión, vasculopatias tales como apoplejía isquémica y aterosclerosis, enfermedades inflamatorias tales como esclerosis múltiple, artritis reumatoide y enfermedad inflamatoria del intestino, toxicomanía, dolor neurópatico, enfermedades pulmonares tales como asma y enfermedad pulmonar obstructiva crónica, cáncer y septicemia. Adicción a las drogas, dolor neuropático, enfermedades pulmonares como asma y enfermedad pulmonar obstructiva crónica, cáncer y sepsis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382567 | 2015-11-16 | ||
| PCT/EP2016/077632 WO2017085034A1 (en) | 2015-11-16 | 2016-11-15 | Gelatinase inhibitors and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005259A true MX2018005259A (es) | 2018-08-16 |
| MX377186B MX377186B (es) | 2025-03-07 |
Family
ID=54754574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005259A MX377186B (es) | 2015-11-16 | 2016-11-15 | Inhibidores de gelatinasa y uso de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10414797B2 (es) |
| EP (1) | EP3377515B1 (es) |
| JP (1) | JP6795606B2 (es) |
| KR (1) | KR102649684B1 (es) |
| CN (1) | CN108290925B (es) |
| AU (1) | AU2016356876B2 (es) |
| BR (1) | BR112018009641A2 (es) |
| CA (1) | CA3002892A1 (es) |
| EA (1) | EA036732B1 (es) |
| ES (1) | ES2766548T3 (es) |
| IL (1) | IL259286B (es) |
| MX (1) | MX377186B (es) |
| WO (1) | WO2017085034A1 (es) |
| ZA (1) | ZA201803212B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107987126B (zh) * | 2017-12-18 | 2018-10-02 | 哈尔滨工业大学 | 4位苯丙酰胺羟基化修饰的内吗啡肽类似物及其合成方法和应用 |
| TW202229306A (zh) * | 2020-11-05 | 2022-08-01 | 日商中外製藥股份有限公司 | 抑制由二酮哌嗪形成所導致之缺陷的胜肽合成方法 |
| EP4714940A1 (en) | 2024-09-23 | 2026-03-25 | Accure Therapeutics, S.L. | Gelatinase inhibitors and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2573006B2 (ja) * | 1987-12-17 | 1997-01-16 | 富士薬品工業株式会社 | 新規なヒドロキサム酸誘導体 |
| AU2228292A (en) | 1991-06-14 | 1993-01-12 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| WO1998015525A1 (en) * | 1996-10-07 | 1998-04-16 | Sumitomo Pharmaceuticals Co., Ltd. | Hydroxamic acids |
| WO2009097893A1 (en) * | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp |
-
2016
- 2016-11-15 ES ES16795077T patent/ES2766548T3/es active Active
- 2016-11-15 US US15/776,296 patent/US10414797B2/en active Active
- 2016-11-15 KR KR1020187016673A patent/KR102649684B1/ko active Active
- 2016-11-15 EA EA201891184A patent/EA036732B1/ru unknown
- 2016-11-15 CN CN201680066867.4A patent/CN108290925B/zh active Active
- 2016-11-15 BR BR112018009641-5A patent/BR112018009641A2/pt not_active Application Discontinuation
- 2016-11-15 CA CA3002892A patent/CA3002892A1/en active Pending
- 2016-11-15 WO PCT/EP2016/077632 patent/WO2017085034A1/en not_active Ceased
- 2016-11-15 MX MX2018005259A patent/MX377186B/es active IP Right Grant
- 2016-11-15 EP EP16795077.3A patent/EP3377515B1/en active Active
- 2016-11-15 AU AU2016356876A patent/AU2016356876B2/en active Active
- 2016-11-15 JP JP2018544414A patent/JP6795606B2/ja active Active
-
2018
- 2018-05-10 IL IL259286A patent/IL259286B/en unknown
- 2018-05-15 ZA ZA2018/03212A patent/ZA201803212B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL259286A (en) | 2018-07-31 |
| NZ741898A (en) | 2024-02-23 |
| US10414797B2 (en) | 2019-09-17 |
| EP3377515A1 (en) | 2018-09-26 |
| CA3002892A1 (en) | 2017-05-26 |
| EA036732B1 (ru) | 2020-12-14 |
| HK1255029A1 (en) | 2019-08-02 |
| JP6795606B2 (ja) | 2020-12-02 |
| CN108290925A (zh) | 2018-07-17 |
| US20180319839A1 (en) | 2018-11-08 |
| WO2017085034A1 (en) | 2017-05-26 |
| EP3377515B1 (en) | 2019-10-30 |
| AU2016356876B2 (en) | 2020-10-01 |
| MX377186B (es) | 2025-03-07 |
| KR20180071388A (ko) | 2018-06-27 |
| ES2766548T3 (es) | 2020-06-12 |
| IL259286B (en) | 2021-10-31 |
| AU2016356876A1 (en) | 2018-05-10 |
| ZA201803212B (en) | 2020-08-26 |
| JP2018535258A (ja) | 2018-11-29 |
| BR112018009641A2 (pt) | 2018-11-06 |
| KR102649684B1 (ko) | 2024-03-21 |
| CN108290925B (zh) | 2021-12-24 |
| EA201891184A1 (ru) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| BR112014014809A8 (pt) | composições farmacêuticas compreendendo glitazonas e ativadores de nrf2 | |
| MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| UA117218C2 (uk) | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f | |
| UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
| MX395415B (es) | Sal de acido maleico de {5-[4-(1,1-dioxo-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropancarboxilico | |
| BR112012009327A2 (pt) | análogos de heterociclil pirazolopirimidina como inibidores de jak | |
| CL2013003512A1 (es) | Compuestos derivados de 7-(heterociclilo, arilo o heteroarilo) de piridopirazinas o sus sales; composicion farmaceutica que los comprende, utiles para el tratamiento de una enfermedad mediada por ptk quinasa tales como asma alergica, rinitis alergica, artritis reumatoide, esclerosis multiple, lupus, leucopenia, entre otras enfermedades. | |
| EP3434645A4 (en) | METHOD FOR CONTINUOUS PRODUCTION OF GRAPHIC OXIDE NANOPLATES | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| BR112015021495A2 (pt) | fabricação contínua integrada de substâncias de droga de proteína terapêutica | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| ECSP17046848A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis | |
| MX386256B (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
| EP2849738A4 (en) | HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES | |
| IT201600079633A1 (it) | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico | |
| IT201700081449A1 (it) | Procedimento di purificazione dell'acido ialuronico | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| MX2018009802A (es) | Composiciones novedosas y metodos terapeuticos. | |
| AR087168A1 (es) | Compuesto derivado de pirimidina sulfonamida | |
| BR112013030264A2 (pt) | ácidos acéticos de benzociclohepteno | |
| CO2017002982A2 (es) | Compuesto de pirazolotiazol y medicamento que comprende el mismo | |
| CU20160156A7 (es) | Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: ACCURE THERAPEUTICS, S.L. |